爱美医疗 FOLD 深 沪
等待开盘 05-20 09:30:00 美东时间
14.49
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 14.49
- 总市值 45.50亿
- 52周最高 14.50
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 5.51
- 委 比 0.00%
- 总股本 3.14亿
- 历史最高 25.39
- 量 比 0
- 振 幅 0.00%
- 历史最低 1.765
- 每 手 1
- 风险率 3.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BioMarin Pharmaceutical Receives Approval From France's Ministry Of Economics And Finance For Proposed Merger With Amicus Therapeutics
https://www.sec.gov/ix?doc=/Archives/edgar/data/1048477/000119312526173770/d139584d8k.htm
04-24 04:56
Top 10 Healthcare stocks by forward P/E: From Capricor's 418x to Alignment Healthcare's 48x
A Bank of America Global Research chart tracking healthcare R&D-to-sales ratios and relative forward PE versus the S&P 500 from 1990 to March 2026 shows both metrics declining in tandem over decades, ...
04-17 04:04
新浪财经ESG：爱美医疗 MSCI（明晟）ESG评级调降至B
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
03-24 10:13
Amicus Therapeutics President and CEO Bradley L Campbell Disposes of Common Shares
Amicus Therapeutics President and CEO Bradley L Campbell Disposes of Common Shares Bradley L. Campbell, President and CEO and a director of Amicus Therapeutics Inc., reported a disposal of common shares. The full filing can be accessed through the link below. Disclaimer: This news brief was created
03-05 08:55
BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients
The FDA approved BioMarin's supplemental BLA for Palynziq, a treatment for PKU in adolescents 12 and older.
03-02 19:10
Legal Challenges Loom Over Amicus–BioMarin Merger, Raising Execution and Shareholder Risks
Amicus Therapeutics (FOLD) has disclosed a new risk, in the Litigation & Le...
02-22 14:05
财报速睇 | 爱美医疗 2025财年Q4营收1.85亿美元，同比增长23.7%；归母净利润0.02亿美元，同比下滑88.5%
华盛资讯2月21日讯，爱美医疗公布2025财年Q4业绩，公司Q4营收1.85亿美元，同比增长23.7%，归母净利润0.02亿美元，同比下滑88.5%。
02-21 05:17
Amicus Therapeutics Q4 Adj. EPS $0.10 Beats $0.08 Estimate, Sales $185.213M Beat $179.764M Estimate
Amicus Therapeutics (NASDAQ:FOLD) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.08 by 19.05 percent. This is a 11.11 percent increase over earnings of $0.09 per share from
02-21 05:05
BRIEF-Amicus Therapeutics Q4 Revenue USD 185.2 Million Vs. IBES Estimate USD 180.7 Million
BRIEF-Amicus Therapeutics Q4 Revenue USD 185.2 Million Vs. IBES Estimate USD 180.7 Million Feb 20 (Reuters) - Amicus Therapeutics Q4 net income USD 1.7 million. Q4 EPS USD 0.01
02-21 05:01
